<qa>  What was the EGFRmut phase II group 1?- Phase II Group 1 EGFRmut, any T790M, any c-MET, 24L antineoplastic, EGFR TKI resistant only: Patients demonstrated a documented clinical benefit CR any duration, PR any duration, or SD for at least 6 months on prior EGFR TKI e.g. erlotinib, gefitinib or afatinib, and subsequently demonstrated progression according to RECIST v1.1. 